Minibeam Radiation Therapy With Tungsten Slit Collimator for the Treatment of Recurrent or Metastatic Skin or Soft Tissue Tumors

PRIMARY OBJECTIVE:

I. To determine the maximum tolerated dose (MTD) of MBRT and describe the adverse events of treatment.

SECONDARY OBJECTIVE:

I. To assess the ability to maintain a distinct differential between peak and valley doses using film dosimetry.

EXPLORATORY OBJECTIVES:

I. To estimate the rate of freedom from local progression at 6 and 12 months after the start of MBRT.

II. To evaluate pre-treatment and post-treatment differential abundance of peripheral blood immune cell populations and their activation markers.

III. Explore germline and somatic mutations in homologous recombination (HR) genes and their association with freedom from local progression.

IV. Quantify the immune phenotypes and cell signaling in the tumor microenvironment pre-MBRT and post-MBRT using bulk ribonucleic acid (RNA)-sequencing (seq) data.

OUTLINE:

Patients undergo MBRT with a tungsten slit collimator over 2-3 fractions on study. Patients also undergo standard of care CT simulation on study and undergo collection of blood samples and punch or core biopsy throughout the study.

After completion of study treatment, patients are followed up at weeks 2, 4, and 12, and months 6, 9, and 12.

Inclusion criteria

• Age ≥ 18 years
• Histologically confirmed malignancy
• Primary, recurrent, or metastatic skin or superficial soft tissue tumor amenable to palliative orthovoltage radiotherapy
• Anticipated life expectancy ≥ 30 days and anticipated capacity for follow up for ≥ 30 days
• Negative pregnancy test done ≤ 28 days prior to registration, for biological women of childbearing potential only
• Willing to provide written informed consent
• Willing to allow baseline and follow up photograph acquisition for response and toxicity assessment
• Willing and able to return to enrolling institution for follow-up during the active monitoring phase of the study
• Willing to provide blood and tissue samples for correlative research purposes

Exclusion criteria

• Hematologic, germ cell, or any other tumor that the investigational team would deem to have a high likelihood of clinical complete response with standard palliative radiotherapy (8 Gy in 1, 30 Gy in 10, etc.)
• COHORT A (INTACT SKIN) ONLY: Prior radiotherapy targeting the lesion presenting for treatment or prior adjacent radiotherapy if > 10 Gy overlaps with a portion of the planned target
• Treatment with a B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitor, monoclonal antibodies targeting vascular endothelial growth factor (VEGF) (bevacizumab or ramucirumab) or small molecule inhibitors inhibiting VEGF within the last 2 weeks or planned treatment with BRAF inhibitor within 4 weeks after radiation
• Treatment with an investigational drug therapy within 2 weeks prior to or 4 weeks (the DLT monitoring period) after MBRT
• Any tumor with direct extension into the spine such that targeting the spine/spinal cord could not be avoided